@xconomy.com 9 days ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com 18 days ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com 22 days ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com 23 days ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com 24 days ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com 1 month ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com 2 months ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com 2 months ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com 5 months ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 6 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 7 months ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com 7 months ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com 7 months ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com 8 months ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com 8 months ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com 8 months ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com 8 months ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com 8 months ago
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy
@xconomy.com 9 months ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com 9 months ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com 10 months ago
Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow
@xconomy.com 11 months ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com 11 months ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com 11 months ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com 11 months ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com 12 months ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com 1 year ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com 1 year ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com 1 year ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com 1 year ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com 1 year ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com 1 year ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com 1 year ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 1 year ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com 1 year ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com 1 year ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com 1 year ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com 1 year ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com 1 year ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com 1 year ago
White House Floats Canadian Import Plan But Excludes Many Costly Drugs
@xconomy.com 1 year ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com 1 year ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com 1 year ago
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome
@xconomy.com 1 year ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com 1 year ago
Review: Inside the House of Lies at Theranos
@xconomy.com 1 year ago
Invitae Offers $55M for Singular Bio to Expand Prenatal Test Business
@xconomy.com 1 year ago
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes
@xconomy.com 1 year ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?